natgillin/translations-raw huggingface dataset:
M98-940 er et åbent studie af en flydende formulering af Kaletra med 100 pædiatriske patienter, der enten var antiretroviralt behandlingsnaive (44 %) eller med forudgående behandling med antiretrovirale midler (56 %).
M98-940 was an open-label study of a liquid formulation of Kaletra in 100 antiretroviral naïve (44%) and experienced (56%) paediatric patients.
Ma
Mon
MA 01701-9322 USA
Framingham, MA 01701-9322 USA
MA 01757 USA
MA 01757 UNITED STATES
MA TI ON TO FR LØ SØ
MON TUE WED THU FRI SAT SUN
Ma Ti On To Fr Lø Sø
Tue Wed Thu Fri Sat Sun
Maagdarmsteselaandoeningen
Gastrointestinal disorders
MabCampath 10 mg/ml koncentrat til infusionsvæske, opløsning
MabCampath 10 mg/ml concentrate for solution for infusion
MabCampath 10 mg/ml koncentrat til infusionsvæske.
MabCampath 10 mg/ml concentrate for solution for infusion
MabCampath 30 mg/ml koncentrat til infusionsvæske, opløsning.
MabCampath 30 mg/ml concentrate for solution for infusion
MabCampath 30 mg/ml koncentrat til infusionsvæske.
MabCampath 30 mg/ml concentrate for solution for infusion
MabCampath 30 mg/ml, koncentrat til infusionsvæske, opløsning Alemtuzumab
MabCampath 30 mg/ml concentrate for solution for infusion Alemtuzumab
MabCampath administreres ind i en af dine vener via et drop (se også ‘oplysninger tiltænkt læger og sundhedspersonale’).
MabCampath is administered into one of your veins via a drip (see also ‘information intended for medical or healthcare professionals’).
MabCampath administreres ind i en af dine vener via et drop (se også ’oplysninger tiltænkt læger og sundhedspersonale’).
MabCampath is administered into one of your veins via a drip (see also ‘information intended for medical or healthcare professionals’).
MabCampath anvendes til behandling af patienter med B-celle kronisk lymfatisk leukæmi (B-CLL), som er kræftform i en type hvide blodlegemer kaldet B-lymfocytter..
MabCampath is used to treat patients with B-cell chronic lymphocytic leukaemia (B-CLL), a cancer of a type of white blood cell called B lymphocytes.
MabCampath anvendes til patienter, hos hvem kombinationsbehandlinger, der omfatter fludarabin (et andet lægemiddel, der bruges mod leukæmi), ikke er hensigtsmæssige.
MabCampath is used in patients for whom treatment combinations including fludarabine (another medicine used in leukaemia) are not appropriate.
MabCampath blev oprindeligt godkendt under ”særlige omstændigheder”, da det af faglige årsager ikke har været muligt at indhente fyldestgørende oplysninger om lægemidlet.
MabCampath was originally authorised under ‘exceptional circumstances’, because, for scientific reasons, it had not been possible to obtain complete information on the medicine.
MabCampath bør indgives under kontrol af en læge med erfaring i cancerbehandling.
MabCampath should be administered under the supervision of a physician experienced in the use of cancer therapy.
MabCampath bør seponeres permanent, hvis autoimmun anæmi eller autoimmun trombocytopeni forekommer.
MabCampath should be permanently discontinued if autoimmune anaemia or autoimmune thrombocytopenia appears.
MabCampath er en koncentreret opløsning til infusion, der leveres i et hætteglas.
MabCampath is a concentrate for solution for infusion that comes in a glass vial.
MabCampath er indiceret til behandling af patienter med kronisk lymfatisk B-celleleukæmi (B-CLL) for hvem fludarabin-kombinationskemoterapi ikke er hensigtsmæssig.
MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (B- CLL) for whom fludarabine combination chemotherapy is not appropriate.
MabCampath gives med 30 mg 3 gange om ugen på skiftende dage i op til 12 uger.
MabCampath will be given at 30 mg three times per calendar week on alternate days, for up to 12 weeks.
MabCampath må ikke anvendes til børn under 17 år eller til patienter, som har nyre- eller leverlidelser.
MabCampath is not recommended in children below 17 years of age or in patients who have kidney or liver disorders.
MabCampath må ikke gives til patienter, som er gravide, og derfor skal du, hvis du:
MabCampath must not be administered to patients who are pregnant, therefore if you:
MabCampath skal seponeres permanent, hvis der opstår autoimmun anæmi eller autoimmun trombocytopeni.
MabCampath should be permanently discontinued if autoimmune anaemia or autoimmune thrombocytopenia appears.
MabCampath viste sig at være chlorambucil overlegent målt ved det primære effektmål progressionsfri overlevelse (PFS) (se Figur 1).
MabCampath was shown to be superior to chlorambucil as measured by the primary endpoint progression free survival (PFS) (see Figure 1).
MabCampaths sikkerhed og virkning hos børn under 17 år er ikke klarlagt.
The safety and efficacy of MabCampath in children aged less than 17 years of age have not been established.
MabThera +MTX 2 × 1.000 mg
MabThera +MTX 2 × 1000 mg
MabThera +MTX 2 × 1.000 mg
MabThera+MTX 2 × 1000 mg
MabThera 100 mg koncentrat til infusionsvæske, opløsning
MabThera 100 mg concentrate for solution for infusion
MabThera 100 mg koncentrat til infusionsvæske, opløsning rituximab
MabThera 100 mg concentrate for solution for infusion rituximab
MabThera 100 mg, koncentrat til infusionsvæske, opløsning Rituximab
MabThera 100 mg concentrate for solution for infusion Rituximab
MabThera 1400 mg anvendes til behandling af non-Hodgkin-lymfom hos voksne.
MabThera 1400 mg is used to treat Non-Hodgkin’s lymphoma in adults.
MabThera 1400 mg opløsning til subkutan injektion
MabThera 1400 mg solution for subcutaneous injection
MabThera 1400 mg, opløsning til subkutan injektion rituximab
MabThera 1400 mg solution for subcutaneous injection rituximab
MabThera 1600 mg opløsning til subkutan injektion
MabThera 1600 mg solution for subcutaneous injection
MabThera 1600 mg, opløsning til subkutan injektion rituximab
MabThera 1600 mg solution for subcutaneous injection rituximab
MabThera 500 mg koncentrat til infusionsvæske, opløsning
MabThera 500 mg concentrate for solution for infusion
MabThera 500 mg koncentrat til infusionsvæske, opløsning rituximab
MabThera 500 mg concentrate for solution for infusion rituximab
MabThera 500 mg, koncentrat til infusionsvæske, opløsning Rituximab
MabThera 500 mg concentrate for solution for infusion Rituximab
MabThera blev givet på den første dag i en behandlingsserie.
MabThera was administered on the first day of the treatment cycle.
MabThera bør anvendes i kombination med CHOP-kemoterapi.
MabThera should be used in combination with CHOP chemotherapy.
MabThera er forbundet med infusionsrelaterede reaktioner (IRR), som kan være relaterede til frigivelse af cytokiner og/eller andre kemiske mediatorer.
MabThera is associated with infusion related reactions (IRRs), which may be related to release of cytokines and/or other chemical mediators.
MabThera er forbundet med infusionsrelaterede reaktioner, der kan være relateret til frigivelse af cytokiner og/eller andre kemiske mediatorer.
MabThera is associated with infusion/ related reactions, which may be related to release of cytokines and/or other chemical mediators.
MabThera er forbundet med infusionsrelaterede reaktioner, der kan være relateret til frigivelse af cytokiner og/eller andre kemiske mediatorer.
MabThera is associated with infusionrelated reactions, which may be related to release of cytokines and/or other chemical mediators.
MabThera er i kombination med glukokortikoider indiceret til induktion af remission hos voksne patienter med svær, aktiv granulomatose med polyangiitis (Wegeners granulomatose) (GPA) eller mikroskopisk polyangiitis (MPA).
MabThera, in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).
MabThera er i kombination med kemoterapi indiceret til behandling af kronisk lymfatisk leukæmi hos patienter, som ikke tidligere er behandlet, og til patienter med relaps/refraktær kronisk lymfatisk leukæmi.
MabThera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL.
MabThera er indiceret hos voksne til følgende indikationer: Non-Hodgkin-lymfom (NHL)
MabThera is indicated in adults for the following indications: Non-Hodgkin’s lymphoma (NHL)
MabThera er indiceret hos voksne til Non-Hodgkin-lymfom (NHL):
MabThera is indicated in adults for Non-Hodgkin’s lymphoma (NHL):
MabThera er, i kombination med CHOP-kemoterapi (cyclophosphamid, doxorubicin, vincristin og prednisolon), indiceret til behandling af patienter med CD20 positivt, diffust storcellet B-celle non- Hodgkin-lymfom.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
MabThera er, i kombination med CHOP-kemoterapi (cyclophosphamid, doxorubicin, vincristin og prednisolon), indiceret til behandling af patienter med CD20 positivt, diffust storcellet B-celle non-Hodgkin-lymfom.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
MabThera er, i kombination med CHOP-kemoterapi (cyklofosfamid, doxorubicin, vinkristin og prednisolon), indiceret til behandling af patienter med CD20-positivt, diffust storcellet B-celle non- Hodgkin-lymfom.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
MabThera fås som et koncentrat, der tilberedes til en opløsning til infusion og som en brugsklar opløsning til injektion under huden.
MabThera is available as a concentrate that is made up into the solution for infusion and as a ready- made solution for the injection under the skin.
MabThera fås som medicin, der gives i drop (MabThera 100 mg eller 500 mg koncentrat til opløsning til infusion) og som medicin, der gives som indsprøjtning under huden (MabThera 1400 mg eller MabThera 1600 mg, opløsning til subkutan injektion).
MabThera is available as a medicine given as a drip (called MabThera 100 mg or MabThera 500 mg, concentrate for solution for infusion) and as a medicine for injection under your skin: called MabThera 1400 mg or MabThera 1600 mg, solution for subcutaneous injection).
MabThera gives altid i et drop (intravenøs infusion).
You will always be given MabThera as a drip (intra-venous infusion)..
MabThera gives samme dag som kemoterapien.
MabThera will be given to you on the same day as your chemotherapy.
MabThera i kombination med kemoterapi, ødelægger de unormale celler som gradvist fjernes fra kroppen ved naturlige processer.
MabThera in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes-.
MabThera i kombination med methotrexat øgede signifikant andelen af patienter, der opnåede mindst 20 % forbedring i ACR-score, sammenlignet med patienter behandlet med methotrexat alene (tabel 10).
MabThera in combination with methotrexate significantly increased the proportion of patients achieving at least a 20 % improvement in ACR score compared with patients treated with methotrexate alone (Table 10).
MabThera i kombination med methotrexat øgede signifikant andelen af patienter, der opnåede mindst 20 % forbedring i ACR-score, sammenlignet med patienter behandlet med methotrexat alene (tabel 10).
MabThera in combination with methotrexate significantly increased the proportion of patients achieving at least a 20% improvement in ACR score compared with patients treated with methotrexate alone (Table 10).
MabThera inducerede B-cellereduktion hos 70 % til 80 % af patienterne, men blev kun ledsaget af nedsat serum-immunglobulin hos en mindre del af patienterne.
MabThera induces B-cell depletion in about 70-80% of patients, but was associated with decreased serum immunoglobulins only in a minority of patients.
MabThera intravenous formulering (n= 205): 8 behandlingsserier med MabThera intravenøs formulering i kombination med op til 8 behandlingsserier CHOP- eller CVP-kemoterapi administreret hver 3. uge.
MabThera intravenous formulation (n= 205): 8 cycles of MabThera intravenous formulation in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks.
MabThera intravenøs (n = 88): 1. serie af MabThera indgivet intravenøs 375 mg/m2 i kombination med kemoterapi efterfulgt af op til 5 serier af MabThera indgivet intravenøst 500 mg/m2 i kombination med kemoterapi.
MabThera intravenous (n= 88): 1st cycle of MabThera intravenous 375 mg/m2 in combination with chemotherapy followed by up to 5 cycles of MabThera intravenous 500 mg/m2 in combination with chemotherapy.
MabThera intravenøs formulering blev givet i standarddosen 375 mg/m2 legemsoverfladeareal.
MabThera intravenous formulation was used at the standard dose of 375 mg/m2 body surface area.
MabThera kan også ændre de resultaterne på de blodprøver, som lægen har bestilt.
MabThera may also cause changes in laboratory tests carried out by your doctor.
MabThera leveres i sterile, pyrogenfri hætteglas uden konserveringmiddel til engangsbrug.
MabThera is provided in sterile, preservative-free, non-pyrogenic, single use vials.
MabThera må ikke anvendes til patienter, der kan være overfølsomme (allergiske) over for rituximab, museproteiner eller andre af indholdsstofferne eller til patienter med svær infektion eller alvorligt svækket immunsystem.
MabThera must not be used in people who are hypersensitive (allergic) to rituximab, mouse proteins or any of the other ingredients or in patients with a severe infection or a severely weakened immune system.
MabThera subkutan (n = 88): 1. serie af MabThera indgivet intravenøs 375 mg/m2 i kombination med kemoterapi samt efterfølgende serier (2-6) af MabThera indgivet subkutant 1600 mg i kombination med kemoterapi.
MabThera subcutaneous (n= 88); 1st cycle of MabThera intravenous 375 mg/m2 in combination with chemotherapy plus subsequent cycles (2-6) of MabThera subcutaneous 1600mg in combination with chemotherapy.
MabThera subkutan formulering (n= 205): første behandlingsserie MabThera intravenøs formulering plus 7 behandlingsserier med MabThera subkutan formulering i kombination med op til 8 behandlingsserier CHOP- eller CVP-kemoterapi administreret hver 3. uge.
MabThera subcutaneous formulation (n= 205): first cycle MabThera intravenous formulation plus 7 cycles of MabThera subcutaneous formulation in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks.
MabThera vedligeholdelsesbehandling bestod af en enkelt infusion med MabThera på 375 mg/m2 legemsoverflade administreret hver tredje måned indtil sygdomsprogression eller i en periode på højst to år.
MabThera maintenance treatment consisted of a single infusion of MabThera at 375 mg/m2 body surface area given every 3 months until disease progression or for a maximum period of two years.
MabThera vedligeholdelsesbehandling gav konsekvent fordel i alle testede prædefinerede undergrupper: Køn (mand, kvinde), alder (< 60 år, ≥ 60 år), FLIPI-score (≤1, 2 eller ≥3), induktionsbehandling (R-CHOP, R-CVP eller R-FCM) og uanset kvaliteten af respons på induktionsbehandling (CR, CRu eller PR).
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (< 60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR, CRu or PR).
MabThera vedligeholdelsesbehandling gav konsekvent fordel i alle testede prædefinerede undergrupper: Køn (mand, kvinde), alder (< 60 år, ≥ 60 år), FLIPI-score (≤1, 2 eller ≥3), induktionsbehandling (R-CHOP, R-CVP eller R-FCM) og uanset kvaliteten af respons på induktionsbehandling (CR, CRu eller PR).
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR,CRu or PR).
MabThera+MTX (2 x 1.000 mg)
MabThera+MTX (2 x 1000 mg)
MabThera--patientkort for ikke-onkologiske indikationer
PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS
MabThera-vedligeholdelsesbehandling gav konsekvent fordel i alle testede prædefinerede undergrupper: Køn (mand, kvinde), alder (< 60 år, ≥ 60 år), FLIPI-score (≤1, 2 eller ≥3), induktionsbehandling (R-CHOP, R-CVP eller R-FCM) og uanset kvalitet af respons på induktionsbehandling (CR, CRu eller PR).
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (< 60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR/CRu or PR).
MabTheras effekt og sikkerhed i vedligeholdelsesbehandling er ikke fastslået.
The efficacy and safety of MabThera in maintenance therapy has not been established.
MabTheras sikkerhedsprofil ved non-Hodgkin-lymfom og kronisk lymfatisk leukæmi er baseret på data fra patienter fra kliniske studier og overvågning efter markedsføring.
The overall safety profile of MabThera in non-Hodgkin’s lymphoma and CLL is based on data from patients from clinical trials and from post-marketing surveillance.
MabThera’s sikkerhedsprofil ved non-Hodgkin-lymfom og kronisk lymfatisk leukæmi er baseret på data fra patienter fra kliniske studier og fra post-marketing overvågning.
The overall safety profile of MabThera in non-Hodgkin’s lymphoma and CLL is based on data from patients from clinical trials and from post-marketing surveillance.
Macclesfield, Cheshire SK10 2NA Storbritannien
Macclesfield, Cheshire SK10 2NA United Kingdom
Macclesfield, Cheshire, SK10 2NA Storbritannien
Macclesfield, Cheshire, SK10 2NA United Kingdom
MACE
1059
MACE bekræftet af en bedømmelseskomite blev rapporteret hos 52 ud af 3182 (1,6 %) patienter i alirocumab-gruppen og 33 ud af 1792 (1,8 %) patienter i kontrolgruppen (placebo eller aktiv kontrol); HR=0,81 (95 % CI, 0,52 til 1,25).
MACE confirmed by adjudication were reported in 52 of 3182 (1.6%) patients in the alirocumab group and 33 of 1792 (1.8%) patients in the control group (placebo or active control); HR=0.81 (95% CI, 0.52 to 1.25).
MACE indberettet i studiet med kardiovaskulære endepunkter
MACE Reported in cardiovascular outcomes study
MACE indberettet i studiet medkardiovaskulære endepunkter
MACE Reported in cardiovascular outcomes study
MACI 500.000 - 1.000.000 celler/cm2 implantationsmatrix
MACI 500,000 - 1,000,000 cells/cm2 implantation matrix
MACI 500.000 til 1.000.000 celler/cm2 implantationsmatrix
MACI 500,000 to 1,000,000 cells/cm2 implantation matrix
MACI er et lægemiddel til avanceret terapi, som kaldes et “produkt fremstillet ved vævsteknik”.
MACI is an advanced therapy product called a ‘tissue engineered product’.
MACI er indiceret til reparation af symptomatiske bruskdefekter i knæet, der går helt igennem brusken (grad III og IV på Modified Outerbridge Scale), på 3-20 cm2 hos voksne patienter med et fuldt udvokset skelet.
MACI is indicated for the repair of symptomatic, full-thickness cartilage defects of the knee (grade III and IV of the Modified Outerbridge Scale) of 3-20 cm2 in skeletally mature adult patients.
MACI er undersøgt i et parallelt, randomiseret, åbent studium hos 144 patienter med Outerbridge grad III eller IV fokale bruskdefekter på 3-20 cm2 (median 4 cm2) i knæet.
MACI has been investigated in a parallel, randomised, open-label trial in 144 patients with Outerbridge Grade III or IV focal cartilage defects of the knee of 3-20 cm2 (median 4 cm2).
MACI frigives efter positive resultater af analyser, som vurderer chondrocytternes levedygtighed, identitet, potens, minimum-celleantal, endotoxin, sterilitet før frigivelse og mykoplasma.
MACI will be released following successful results from assays which assess chondrocyte viability, identity, potency, minimum cell number, endotoxin, pre-release sterility, and mycoplasma.
MACI leveres i 1 til 2 skåle, som er placeret i en 95 kPa-pose (ydre pose) med absorberende materiale til transport.
MACI is supplied in 1 to 2 dishes, which are placed into a 95kPa pouch (outer bag) with absorbent material for transport.
MACI-implantatet fastgøres ved hjælp af en fibrinklæber.
MACI will be secured in place using a fibrin sealant.
Macitentan er ikke et substrat for P-gp/MDR-1.
Macitentan is not a substrate for P- gp/MDR-1.
Macitentan kan i mindre grad påvirke evnen til at føre motorkøretøj og betjene maskiner.
Macitentan may have a minor influence on the ability to drive and use machines.
Macitentan1 0 mg (N = 242)
Macitentan 10 mg (N = 242)
Macrogel 400 Titandioxid E171
Macrogol 400 Titanium dioxide E171
Macrogol (3350) Talkum Sojalecithin Indigotin I (E132)
Indigo carmine aluminium lake (E132)
Macrogol 15 hydroxystearat Glycerol (E422)
Macrogol 15 hydroxystearate Glycerol (E422)
Macrogol 15 hydroxystearat Glycerol (E422)
Macrogol 15 hydroxystearate Glycerol (E422) Triglycerides, medium-chain
Macrogol 1500 Meglumin
Macrogol 1500 Meglumine
Macrogol 300 Glycin Dinatriumedetat
Macrogol 300 Glycine Disodium edetate
Macrogol 300 Glycin Natriumcitrat
Macrogol 300 Glycine Sodium citrate
Macrogol 3000 Propylenglycol
Macrogol 3000 (Polyethyleneglycol)
Macrogol 3000 Rød og gul jernoxid Carnaubavoks.
Red and yellow ferric oxides Carnauba wax
Macrogol 3000 Triacetin
Triacetin
Macrogol 3350 Talcum (E553b)
Talc (E553b)
Macrogol 3350 Talcum Sojalecithin
Poly (vinyl alcohol) Titanium dioxide Macrogol 3350 Talc
Macrogol 3350 Talkum (E553b)
Macrogol 3350 Talc (E553b)
Macrogol 400 Bazedoxifen aktivt overtræk
Macrogol 400 Bazedoxifene active coating
Macrogol 400 Ethanol, vandfri Poloxamer 188 Citronsyremonohydrat
Macrogol 400 Ethanol, anhydrous Poloxamer 188
Macrogol 400 Titandioxid
Macrogol 400 Titanium dioxide
Macrogol 400 Vandfri ethanol
Macrogol 400 Anhydrous ethanol
Macrogol 4000 Talcum
Macrogol 4000 Talc
Macrogol 6000 Titandioxid Jernoxid, rød
Macrogol 6000 Titanium dioxide Iron oxide red
Macrogol 6000, kolloid vandfri silica, crospovidon, pulveriseret cellulose, magnesiumstearat.
Macrogol 6000, Colloidal anhydrous silica, Crospovidone, Cellulose powdered, Magnesium stearate.
Macrogol 8000 Titandioxid (E171)
Macrogol 8000 Titanium dioxide (E171)
Macrogol 8000 Titandioxid (E171) Jernoxid, rød (E172)
Macrogol 8000 Titanium dioxide (E171) Ferric oxide, red (E172)
Macrogol 8000 Titandioxid (E171) Jernoxid, rød (E172) Jernoxid, sort (E172)
Macrogol 8000 Titanium dioxide (E171) Ferric oxide, red (E172)
Macrogol Hypromellose (E464)
Hypromellose (E464)
Macrogol Polyvinylalkohol Talcum Titandioxid (E171)
Macrogol Polyvinyl alcohol Talc
Macrogol Talcum
Macrogol Talc
Macrogol, polyvinylalkohol, talcum, titandioxid (E171), jernoxid, sort (E172).
Macrogol, polyvinyl alcohol, talc, titanium dioxide (E171), iron oxide black (E172).
Macrogol, titandioxid (E171), lactosemonohydrat, triacetin, hypromellose, indigocarmin Lake (E132)
Macrogol, Titanium dioxide (E171), Lactose monohydrate, Triacetin, Hypromellose, Indigo Carmin Lake (E132)
Macrogoler type 400 (polyethylen glycol 400) Hydroxypropylcellulose
Macrogols type 400 (Polyethylene glycol 400) Hydroxypropyl cellulose
Macugen 0,3 mg injektionsvæske, opløsning
Macugen 0.3 mg solution for injection
Macugen 0,3 mg injektionsvæske, opløsning Pegaptanib
Macugen 0.3 mg solution for injection pegaptanib
Macugen 0,3 mg injektionsvæske, opløsning Pegaptanibnatrium
Macugen 0.3 mg solution for injection pegaptanib
Macugen 0,3 mg injektionsvæske, opløsning.
Macugen 0.3 mg solution for injection
Macugen 0,3 mg Pegaptanib
Macugen 0.3 mg injection pegaptanib
Macugen anbefales ikke til kvinder, der ammer, da det ikke vides, om Macugen går over i mælken hos mennesker.
Macugen is not recommended during breastfeeding as it is not known whether Macugen passes into human milk.
Macugen anvendes til behandling af voksne med den ”våde” form af aldersrelateret maculadegeneration (AMD).
Macugen is used to treat adults with the ‘wet’ form of age-related macular degeneration (AMD).